Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome

Stručni rad - Uvodnik

• Autor: Predrag Sikirić
• Autor: Anita Škrtić
• Autor: Slaven Gojković
• Autor: Ivan Krezić
• Autor: Helena Žižek
• Autor: Eva Lovrić
• Autor: Sunčana Sikirić
• Autor: Mario Knežević
• Autor: Sanja Štrbe; MBZ: 319335
• Autor: Marija Milavić
• Autor: Antonio Kokot
• Autor: Alenka Boban Blagaić
• Autor: Sven Seiwerth
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA TEMELJNU I KLINIČKU FARMAKOLOGIJU)
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA PATOLOGIJU)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Temeljne medicinske znanosti; Farmakologija
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Patologija

Sažetak (engleski)

The stable gastric pentadecapeptide BPC 157 counteracts various venous occlusion-induced syndromes. Summarized are all these arguments, in the Robert's cytoprotection concept, to substantiate the resolution of different major vessel occlusion disturbances, in particular ischemia-reperfusion injury following the Pringle maneuver and Budd-Chiari syndrome, which was obtained by BPC 157 therapy. Conceptually, there is a new point, namely, endothelium maintenance to epithelium maintenance (the recruitment of collateral blood vessels to compensate for vessel occlusion and reestablish blood flow or bypass the occluded or ruptured vessel). In this paper, we summarize the evidence of the native cytoprotective gastric pentadecapeptide BPC 157, which is stable in the human gastric juice, is a membrane stabilizer and counteracts gut-leaky syndrome. As a particular target, it is distinctive from the standard peptide growth factors, involving particular molecular pathways and controlling VEGF and NO pathways. In the early 1990s, BPC 157 appeared as a late outbreak of the Robert's and Szabo's cytoprotection-organoprotection concept, like the previous theoretical/practical breakthrough in the 1980s and the brain-gut axis and gut-brain axis. As the time went on, with its reported effects, it is likely most useful theory practical implementation and justification. Meantime, several reviews suggest that BPC 157, which does not have a lethal dose, has profound cytoprotective activity, used to be demonstrated in ulcerative colitis and multiple sclerosis trials. Likely, it may bring the theory to practical application, starting with the initial argument, no degradation in human gastric juice for more than 24 h, and thereby, the therapeutic effectiveness (including via a therapeutic per-oral regimen) and pleiotropic beneficial effects.

• Ključne riječi (engleski): Anti-Ulcer Agents; Budd-Chiari Syndrome; Humans; Peptide Fragments; Proteins; Reperfusion Injury / drug therapy; Reperfusion Injury / prevention & control
• Jezik: engleski
• Vrsta publikacije: Stručni rad - Uvodnik
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: World Journal of Gastroenterology
• Brojčani podaci: vol. 28, br. 1, str. 23-46
• p-ISSN: 1007-9327
• DOI: https://doi.org/10.3748/wjg.v28.i1.23
• URN:NBN: urn:nbn:hr:105:440084
• Datum objave publikacije: 2022-01-07
• URL dokumenta: https://www.wjgnet.com/1007-9327/full/v28/i1/23.htm
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2022-11-14 09:17:53